244 related articles for article (PubMed ID: 26773814)
1. Low-dose pembrolizumab induced remission in patients with refractory classical Hodgkin lymphoma.
Kwong YL; Lopes D; Khong PL
Br J Haematol; 2017 Jan; 176(1):131-132. PubMed ID: 26773814
[No Abstract] [Full Text] [Related]
2. Pembrolizumab for classical Hodgkin's lymphoma.
Burki TK
Lancet Oncol; 2016 Aug; 17(8):e324. PubMed ID: 27397043
[No Abstract] [Full Text] [Related]
3. Low-dose pembrolizumab induced complete radiologic and molecular response of posttransplant lymphoproliferative disorder presenting as classical Hodgkin lymphoma.
Sim JPY; Au-Yeung R; Kwong YL
Ann Hematol; 2020 Feb; 99(2):385-388. PubMed ID: 31773213
[No Abstract] [Full Text] [Related]
4. High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy.
Falchi L; Sawas A; Deng C; Amengual JE; Colbourn DS; Lichtenstein EA; Khan KA; Schwartz LH; O'Connor OA
J Hematol Oncol; 2016 Nov; 9(1):132. PubMed ID: 27899158
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab Improves Progression-Free Survival in Relapsed/Refractory Hodgkin Lymphoma.
Oncologist; 2020 Jul; 25 Suppl 1(Suppl 1):S18-S19. PubMed ID: 32588926
[TBL] [Abstract][Full Text] [Related]
6. Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma.
Li X; Cheng Y; Zhang M; Yan J; Li L; Fu X; Zhang X; Chang Y; Sun Z; Yu H; Zhang L; Wang X; Wu J; Li Z; Nan F; Tian L; Li W; Young KH
J Hematol Oncol; 2018 Jan; 11(1):15. PubMed ID: 29386072
[TBL] [Abstract][Full Text] [Related]
7. Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma.
Nie J; Wang C; Liu Y; Yang Q; Mei Q; Dong L; Li X; Liu J; Ku W; Zhang Y; Chen M; An X; Shi L; Brock MV; Bai J; Han W
J Clin Oncol; 2019 Jun; 37(17):1479-1489. PubMed ID: 31039052
[TBL] [Abstract][Full Text] [Related]
8. Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma.
von Tresckow B; Fanale M; Ardeshna KM; Chen R; Meissner J; Morschhauser F; Moskowitz C; Zinzani PL; Giezek H; Balakumaran A; Vo TT; Raut M; Brice P
Leuk Lymphoma; 2019 Nov; 60(11):2705-2711. PubMed ID: 31012356
[TBL] [Abstract][Full Text] [Related]
9. Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphoma.
Ansell SM
Lancet Haematol; 2019 Jan; 6(1):e2-e3. PubMed ID: 30612711
[No Abstract] [Full Text] [Related]
10. Pembrolizumab for Refractory Metastatic Myxofibrosarcoma: A Case Report.
Song HN; Kang MG; Park JR; Hwang JY; Kang JH; Lee WS; Lee GW
Cancer Res Treat; 2018 Oct; 50(4):1458-1461. PubMed ID: 29361819
[TBL] [Abstract][Full Text] [Related]
11. Anti-PD-1 immunotherapy in combination with sequential involved-site radiotherapy in heavily pretreated refractory Hodgkin lymphoma.
Quéro L; Gilardin L; Fumagalli I; Martin V; Guillerm S; Bauduceau O; Kirova YM; Hennequin C; Brice P
Cancer Radiother; 2019 Apr; 23(2):132-137. PubMed ID: 30733172
[TBL] [Abstract][Full Text] [Related]
12. Rituximab plus ABVD in newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma.
Cencini E; Fabbri A; Bocchia M
Br J Haematol; 2017 Mar; 176(5):831-833. PubMed ID: 26913966
[No Abstract] [Full Text] [Related]
13. Unique Case of Pseudoprogression Manifesting as Lung Cavitation After Pembrolizumab Treatment.
Masuhiro K; Shiroyama T; Nagatomo I; Kumanogoh A
J Thorac Oncol; 2019 May; 14(5):e108-e109. PubMed ID: 31027746
[No Abstract] [Full Text] [Related]
14. Role of Pembrolizumab in recurrent or metastatic head and neck carcinoma.
Pellini R; Campo F; Sergi D; Cappuzzo F
Oral Oncol; 2021 Apr; 115():105133. PubMed ID: 33386236
[No Abstract] [Full Text] [Related]
15. Low-dose pembrolizumab for relapsed/refractory Hodgkin lymphoma: high efficacy with minimal toxicity.
Chan TS; Luk TH; Lau JS; Khong PL; Kwong YL
Ann Hematol; 2017 Apr; 96(4):647-651. PubMed ID: 28138786
[TBL] [Abstract][Full Text] [Related]
16. Abscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody.
Michot JM; Mazeron R; Dercle L; Ammari S; Canova C; Marabelle A; Rose S; Rubin E; Deutsch E; Soria JC; Ribrag V; Levy A
Eur J Cancer; 2016 Oct; 66():91-4. PubMed ID: 27544928
[No Abstract] [Full Text] [Related]
17. How I incorporate novel agents into the treatment of classical Hodgkin lymphoma.
Epperla N; Herrera AF
Blood; 2021 Aug; 138(7):520-530. PubMed ID: 33889927
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab activity in relapsed Hodgkin's lymphoma.
Das M
Lancet Oncol; 2017 Apr; 18(4):e205. PubMed ID: 28318993
[No Abstract] [Full Text] [Related]
19. Low-dose pembrolizumab re-treatment induced complete radiologic and molecular remission in Hodgkin lymphoma recurring from a previous relapse successfully treated by pembrolizumab.
Kwong YL; Loong F; Khong PL
Ann Hematol; 2019 Oct; 98(10):2451-2455. PubMed ID: 31332470
[No Abstract] [Full Text] [Related]
20. Pembrolizumab for primary malignant melanoma of the central nervous system.
El Habnouni C; Bléchet C; Bens G
J Neurooncol; 2018 Aug; 139(1):225-227. PubMed ID: 29611049
[No Abstract] [Full Text] [Related]
[Next] [New Search]
